Our Business Model

We provide two modes of service: 

Small-scale  

We provide service to pharmaceutical companies, laboratories or academic institutions to test chemicals on our existing models with the choice of readouts in our portfolio. We are flexible to develop new readouts for your needs as well.  

In this model, end users will not need to optimize and assays on their own. We will use use our premises and infrastructure to provide the best service. Our leading scientific experts will also help designing your assays and choice of readouts for your scientific question. 

Gel production, automated screening and assessment of versatile end readouts (e.g.: imaging, morphological analyses, quantification with high-end deep learning-based algorithms, biochemical measurements, changes in gene expression, multiplex analyses, immunohistochemical detection and many more) will be performed in-house. Detailed results will be provided to the users as hard-copy and in electronic formats.

This service is ideal for testing a small number of chemicals (e.g.: 100-50,000).

Please contact us for specific discussion on every individual case. 

Large-scale

For screening campaigns that require a larger scale of optimization and materials use, we offer a unique assay co-development to the end user. This includes customized optimization of the assays in various automation systems, development of new readouts according to the needs of the user, and advanced data storage and documentation capacity. Licensing terms and conditions can be discussed for long-term adaptation of the technology to the user's premises. 

This model is ideal for screening campaigns that test more than 50,000 compounds/chemicals. Please contact us for specific discussion on every individual case.